AIC
VKTX icon

Ameritas Investment Company’s Viking Therapeutics VKTX Stock Holding History

Ameritas Investment Company’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,000
Closed -$23K – 1754
2018
Q4 		$23K Buy
+3,000
New +$35.9K 0.01% 831

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameritas Investment Company's VKTX Position: Q1 2019 in Review

Ameritas Investment Company sold out of Viking Therapeutics (VKTX) in Q1 2019, closing a stake of 3,000 shares — an estimated $23K sold.

Ameritas Investment Company first reported a position in VKTX in Q4 2018 and held it in 1 quarter. The position peaked at $23K in Q4 2018. 164 funds tracked by Wall St. Rank hold VKTX as of Q1 2019.

  • Ameritas Investment Company reported no remaining Viking Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 3,000 Viking Therapeutics shares in Q1 2019, an estimated $23K.
  • Ameritas Investment Company first reported a position in Viking Therapeutics in Q4 2018 and held it in 1 quarter.
  • Ameritas Investment Company's Viking Therapeutics position peaked at $23K in Q4 2018.
  • 164 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.